Fig. 3

Kaplan-Meier estimates of DFS and OS for pre/peri-menopausal patients (a and b) and post-menopausal patients (c and d). a. The estimated 5-year DFS rate was 90.3% for HER2- patients and 89.6% for HER2+ patients treated with trastuzumab (P = 0.422). HER2-pos-T was associated with significantly better DFS in multivariate analysis (P = 0.013). b. The estimated 5-year OS rate was 97.4% in the HER2-neg group and 96.7% in the HER2-pos-T group (P = 0.557). No difference was observed between these two groups in multivariate analysis (P = 0.080). c. The estimated 5-year DFS rate was 89.3% for HER2- patients and 90.7% for HER2+ patients treated with trastuzumab (P = 0.292). HER2-pos-T was associated with significantly better DFS in multivariate analysis (P = 0.005). d. The estimated 5-year OS rate was 95.0% in the HER2-neg group and 96.0% in the HER2-pos-T group (P = 0.249). HER2-pos-T was associated with significantly better OS in multivariate analysis (P = 0.008)